Agios Q3 2026: record sales, R&D cuts, a 2028 non-GAAP profit goal; shares fall 10%
Did the story change? Mixed
Partly. Agios sales rose 24% from Q2 to $55.4 million, above the $51.95 million consensus Investing.com cited, and it set its first profit goal: non-GAAP profitability in 2028, helped by cutting more than 100 R&D jobs. But it added fewer thalassemia prescriptions than in Q2 and will stop reporting them, and the sickle cell decision is still due Feb 1, 2027. The shares fell about 10% on a day the whole market fell hard.
What it means
- What changed
- Agios set a goal of non-GAAP profitability in 2028 and is cutting more than 35% of its R&D jobs, with savings from 2027.
- What hasn't changed
- The FDA's sickle cell decision is still due Feb 1, 2027, and Agios is still discussing a possible safety program with the agency.
- Next · Dec 12–15, 2026
- Agios has 14 ASH abstracts accepted for presentation or publication, including longer sickle cell data; it plans an AG-236 trial start by year-end.
Closing prices: $28.27 on Nov 5, 2026 (Yahoo Finance, CNBC) and $31.38 on Nov 4 (Nasdaq).
Snapshot at the Nov 5, 2026 close
- Market value
- $1.7B
- Enterprise value
- $784M
- Price/sales
- 12.0×
- EV/sales
- 5.6×
- P/E
- n/m
- Price/FCF
- n/m
- Revenue growth
- +214%
- FCF margin
- −238%
- Net cash
- $907M
Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Nov 5, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $28.27 (close, Yahoo Finance and CNBC); 59.8 million shares (common shares on the cover page of the 10-Q filed Nov 5, 2026). n/m = not meaningful (e.g. negative earnings).
Agios’s thalassemia launch pushed sales to a record, and it now has a date for profit, but the larger question, sickle cell disease, stays open until February. Sales were $55.4 million, up 24% from Q2 and more than four times a year earlier; Agios had given no quarterly total-revenue guidance. Excluding the roughly $5 million stocking benefit Agios cited in Q2, growth from Q2 was about 39% (our calculation).1 Agios also said it is cutting more than a third of its R&D jobs.
Why the stock fell
The shares closed about 9.9% lower at $28.27, their lowest close since June and 24% below where they stood before the FDA’s delay last week (Yahoo Finance and Nasdaq closes, our calculation). It was a hard day across the market: the S&P 500 fell 4.4%, the Nasdaq Composite 5.5% and a biotech fund, XBI, 6.7% (Yahoo Finance, our calculation). Agios did not comment on its share price, and no report establishes a cause.
- Sales of $55.4 million were above the $51.95 million consensus Investing.com cited. Reports conflict on whether earnings per share beat or missed, so we leave that comparison out.
- Agios added 177 thalassemia prescriptions, fewer than the 200 it added in Q2 (our calculation), and said this is the last quarter it will report that figure, as it had said in July. It said Q1 benefited from pent-up demand and that demand is now broadening into community practices.
- Truist Securities (Buy rating) lowered its target to $35 from $37. It said the call centered on sickle cell disease and competition, and that the final label matters for uptake, with approval on Feb 1 still its base case, Investing.com reported.
Did the story change?
In July Agios gave no profit date and spoke of expanding its pipeline “opportunistically”; now it targets non-GAAP profit in 2028 and says it will “progress” its pipeline, with fewer R&D jobs. The table compares Q2 with Q3.
| Driver | Q2 → Q3 2026 | Management: before → now | Signal |
|---|---|---|---|
| Net sales | $44.7M → $55.4M (US $48.7M, outside the US $6.6M) | No total revenue guidance → still none | Better |
| AQVESME prescriptions added | 200 → 177 (619 in total, plus 48 in process) | In July, said reporting would end after Q3 → cutoff reaffirmed | Watch |
| Operating expenses | Reported $155.3M → $132.5M; excluding Q2’s $25M upfront, $130.3M → $132.5M (our calculation) | 2026 about flat vs 2025, excluding the upfront → also excluding about $11M of job-cut costs in Q4 | Unchanged |
| Net loss and cash | −$100.7M → −$65.0M; cash $964.8M → $907.0M | “Financial independence” → same words, plus non-GAAP profitability in 2028 | Better |
| Sickle cell decision | Goal date Nov 1, 2026 → Feb 1, 2027 | “Launch-ready”, in labeling talks that include a possible safety program | Watch |
Sources: Q2 and Q3 releases and 10-Qs; call remarks from the Motley Fool transcript. Prescriptions added and percentage changes are our calculations.
What got better
Thalassemia is now producing real revenue. US sales rose 19% from Q2 by our calculation from the 10-Qs (Agios reports 20%). Sales outside the US rose 74%, driven mainly by European early access programs. Agios said about 75% of patients stay on AQVESME after six months, and that 619 prescriptions equal roughly 15% of its target launch population of about 4,000.
Costs are coming down. R&D fell to $73.5 million from $75.8 million in Q2, excluding the $25 million licensing payment (our calculation). Agios will have cut more than 100 R&D roles by year-end, with savings expected in 2027. Its 10-Q also records the first $3.0 million of income from its retained royalty on vorasidenib, the cancer drug it sold.
What needs watching
The trade-off is plain: Agios is cutting R&D to reach profit, and that goal rests on a sickle cell launch in 2027 that the FDA has not yet approved. The CFO said the 2028 target includes that launch and declined to give 2027 guidance. On the call, Citi analyst Samantha Semenkow asked what a safety program could look like. Chief medical officer Sarah Gheuens said such programs range from education to the stricter AQVESME type, and that she could not say more.
Prescription data will disappear just as the launch moves to harder-to-reach patients. That leaves readers with less direct information about new demand. Agios said in July that revenue would become its main measure because it captures both new patient starts and patients staying on treatment; revenue also reflects distributor deliveries and early-access sales.
A filing detail is worth noting: the 10-Q now names Annora Pharma as the company seeking to sell a generic PYRUKYND. Agios has sued, which Agios says stays FDA approval until the earlier of Aug 17, 2029, or a judgment finding the patents invalid, unenforceable or not infringed. The patent office declined in September to institute a review of one of the challenged patents, and Annora has not challenged the composition-of-matter patent, which runs to 2035.
Does this change the long-term story?
Our read: it adds discipline without settling the main question. Agios had about $60 million of negative free cash flow in the quarter (our calculation)2 and ended September with $907 million in cash, cash equivalents and marketable securities. Whether the 2028 goal holds depends mostly on the sickle cell decision, its label and how a launch goes.
For the full record of filings, dilution and cash, see Agios Pharmaceuticals: The Long View.
Footnotes
-
$55.385M ÷ ($44.745M − about $5M) − 1. This adjusts only the disclosed stocking benefit. ↩
-
Q3 = nine months − six months. Operating cash flow −$235.471M − (−$176.232M) = −$59.239M; capital spending −$3.164M − (−$1.981M) = −$1.183M; free cash flow −$60.422M. ↩
What to watch next
- By year-end 2026
- Planned start of a Phase 2/3 program for AG-236 in polycythemia vera, and proof-of-mechanism data for AG-181 in phenylketonuria.
- Dec 12–15, 2026
- ASH meeting: longer RISE UP data in sickle cell disease and the first clinical data for AG-236.
- Feb 1, 2027
- FDA goal date for mitapivat in sickle cell disease, and whether the label comes with a safety program.
- First half of 2028
- Planned Phase 3 start for cevidoplenib in immune thrombocytopenia.
- 2028
- Agios's goal of non-GAAP profitability, which it says assumes a sickle cell launch in 2027.
Quick questions
Why did Agios stop reporting prescriptions?
Agios said in July that reporting would end after Q3, because revenue captures both new starts and patients staying on treatment. Its Q3 release shows 619 cumulative prescriptions with completed start forms, plus 48 in process.
Does Agios expect to become profitable?
Its goal is non-GAAP profitability in 2028, which it says includes a potential sickle cell launch in 2027 and managing operating costs. It has not given 2027 guidance.
Is a generic version of Agios's drug coming?
Annora Pharma has asked the FDA to approve a generic PYRUKYND, and Agios has sued. Agios says the suit stays FDA approval until the earlier of Aug 17, 2029, or a judgment finding the patents invalid, unenforceable or not infringed. Annora has not challenged the composition-of-matter patent, which runs to 2035.
About Agios: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
+ 7 more
Accessed Nov 5, 2026: Motley Fool: Agios Q3 2026 earnings call transcript (Nov 5, 2026) · Investing.com: Truist cuts Agios price target (Nov 2026) · Agios: Q2 2026 results (SEC 8-K, Exhibit 99.1) · Earnings Calls: Agios Q2 2026 call transcript (Jul 30, 2026) · Agios: Q2 2026 Form 10-Q · AP: stocks fall on Nov 5, 2026 · Nasdaq: AGIO historical closes
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.